Cannabis reduces the risk of epilepsy

Epileptics had less than 43.9 percent of the epileptic crisis after receiving a cannabis drug remedy. Crash crash causes damage to the muscular tissue that lasts less than 15 seconds.
A cannabis remedy reduces epilepsy cases by reducing close to 50 percent of epileptic seizures, a new study suggests.

Lennox-Gastaut syndrome patients, who are in serious condition, are likely to reduce epileptic seizures by 43.9 percent if they receive this medicine every day for 14 weeks, according to a recent US study.

"Additional treating is an indispensable requirement for patients who suffer from uncontrolled epileptic crises and hence more hope for those who live in these conditions," says Christina SanIncencio, executive director of the Lennox-Gastaut Syndrome Foundation, transmeton GazetaExpress.

The drug, known as Epidiolex, contains cannabidiol, a nutritional substance derived from cannabis reportedly possessing great medical benefits and is reported to help people suffering from migraines, psoriasis (skin disease), acne and depression.

Cannabidiol does not contain THC, meaning it is not the psychoactive component of cannabis that makes humans "high" (psychotic condition after taking cannabis in cigarette form).

How did this discovery come?
Researchers from the Massachusetts Medical Center have analyzed 171 patients with Lennos-Gastaut syndrome between two and 55 years of age.

Scientists have researched the impact of cannabidiol by adding to their therapy and controlled epileptic seizures in patients with treatment forms under conditions.

At the beginning of the study, unhealthy patients have experienced two epileptic seizures per week every month.

They took about 20mg / kg of cannabidiol every day or sedative steps for 14 weeks.

"These results provide hope".
Further results showed that the calming step initially reduced epileptic seizures to 21.8 per cent.

"Additional treatments were provided for the patients in need who continued to suffer from uncontrolled epileptic seizures and these results offer more than hope for those who live in these conditions," said Ms. SanInocensio.

Although most of the side effects are mild, complications occurred in 86 percent of patients who received cannabidiol including diarrhea, sleepiness, and appetite outbreak.

The new discovery was published in the journal The Lancet.